Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis
β Scribed by Ann Knight; Johan Askling; Anders Ekbom
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- French
- Weight
- 67 KB
- Volume
- 100
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Wegener's granulomatosis is necrotizing granulomatous vasculitis of unknown origin, which untreated has a high mortality within the first year of onset. The introduction of corticosteroids and cyclophosphamide in the treatment has considerably improved survival rates, but past studies have indicated an increased cancer risk, including an increased risk for urinary bladder cancer. No large assessment of the general cancer occurrence in Wegener's granulomatosis has been reported. The aim of our study was to assess the general incidence of cancer in patients with Wegener's granulomatosis and to put this in relation to the risk for bladder cancer. We identified a populationβbased cohort of 1,065 patients with Wegener's granulomatosis in the Swedish Inβpatient Register. Through linkage with the Swedish Cancer Register, we followed the cohort for cancer occurrence for up to 26 years. Standardized incidence ratios (SIR) between observed and expected numbers of cancers were used as a measure of relative risk. There was a 2βfold overall increased risk for cancer in the cohort. The increase was most pronounced for bladder cancer (SIR = 4.8; 95% CI 2.6β8.1), squamous cell skin cancer (SIR = 7.3; 95% CI 4.4β12), leukemias (SIR = 5.7; 95% CI 2.3β12) and for malignant lymphomas (SIR = 4.2; 95% CI 4.2β8.3). The results confirm previous indications of an increased risk for cancer of the urinary bladder but also points to increased risks for cancer at other sites. Β© 2002 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Abstract ## Objective To determine predictors of survival of patients with systemic Wegener's granulomatosis (WG). ## Methods We retrospectively studied 93 patients (median age 52 years, male/female ratio 1.7) with systemic WG. All subjects received cytotoxic drugs. Survival was evaluated as
## Abstract ## Objective An association between therapeutic inhibition of tumor necrosis factor (TNF) and solid malignancies was observed during the Wegener's Granulomatosis Etanercept Trial (WGET), which included 180 patients with granulomatosis with polyangiitis (Wegener's) (GPA). The present st